After a five-year pilot, only one company has successfully taken a test through parallel review, but there is growing industry interest.
The company hopes to simultaneously achieve premarket FDA approval and a national coverage determination from CMS for its NGS cancer panel.
Originally published April 23.
Originally published April 2.
Originally published Dec. 5.
By Turna Ray
This article has been updated to note that Exact Sciences has previously said it will submit the Cologuard test for parallel review by FDA and CMS. Originally published Oct. 7.
NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.
The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.
National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.
In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.